1 April 2025 MSD, Novartis and Eli Lilly are among those whose multi-billion-dollar patents are hurtling towards expiration, writes Marisa Woutersen.
27 March 2025
Latest Features
Europe
Supplementary Protection Certificate rules interpreted in different ways have left the EU’s generic and biosimilar industries hungry for clarity, explains Jiri Slavik of Adalvo.
Unified Patent Court
The UPC Court of Appeal’s approach to delivering a preliminary injunction in a glucose sensor dispute has far-reaching effects, as Wouter Pors of Bird & Bird explains.
Americas
Smaller US companies can now choose to take on much larger, foreign opponents at the ITC, explain Cristen Corry, Paul Ainsworth and Uma Everett of Sterne Kessler.
Americas
Will this year be defined by a concerted shift towards ‘One Health’? Simon Kiddle and Rebecca Tollervey of Mewburn Ellis explore.
Americas
Key developments for the industry this year include a more pro-patent administration and USPTO changes, say Carla Ji-Eun Kim and Deborah Sterling of Sterne Kessler.
Americas
The act’s one-sided provisions and its disproportionate remedies cannot pass constitutional muster, argues John Cox of Barnes & Thornburg.
Americas
Key similarities and differences between the patent systems, particularly in biotech, offer lessons and opportunities for rightsholders, say Daniela Fasoli of Simões Propriedade Intelectual and Jeffrey Morton of Haynes and Boone.
Asia
Free trade zones in Beijing, Shanghai, Guangdong, and Hainan are designed to attract capital into China’s fast-growing healthcare sectors, says Li Mi of Lusheng.
More News
25 March 2025 Danish biotech prepares defence against allegations of trade secret misappropriation | AbbVie claims two former employees helped ProfoundBio use confidential tech to improve its cancer treatment pipeline ahead of Genmab acquisition.
20 March 2025 New hope for 10x’ preliminary injunction after EPO Opposition Division ruling | Patent at issue concerns single-cell spatial molecular imaging products.
20 March 2025 Trio files multiple patent infringement lawsuits to protect blockbuster prostate cancer drug | Latest suits target Hetero and Aizant, following similar actions against Apotex, BDR Pharmaceuticals, and CIPLA.
18 March 2025 Companies are transforming IP from a defensive tool into a revenue-generating powerhouse. Marisa Woutersen at the WIPR Summit 2025 hears trends in licensing, platform-based monetisation, and litigation funding.
18 March 2025 Complaint centres on AI-powered tools for cancer diagnostics | Tempus says its rival has a history of deliberately copying competitors’ technologies.
13 March 2025 As IP professionals wait for agency cutbacks to be felt down the chain, the advice is to stay informed, manage budgets wisely, and use a mix of protections to weather any disruption, finds Marisa Woutersen.
13 March 2025 If law firms begin to fear the political repercussions of doing their jobs, the ‘whole system could unravel’. Muireann Bolger finds a concerned profession looking for leaders to oppose ‘open retribution’.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox